What Is a Biomarker in Cancer and Why Does It Matter?

By: David Grew MD MPH

“Tumor markers are clues, not verdicts. They are helpful tools, but they rarely tell the whole story on their own.”

∗ ∗ ∗

If you or a loved one has cancer, you may hear your doctor mention the word biomarker. For many patients, this is one more unfamiliar term dropped into an already overwhelming conversation.

It can sound abstract. Technical. Maybe even a little intimidating.

But the basic idea is actually pretty simple.

A biomarker is a measurable feature of a cancer, or sometimes of the body, that gives doctors useful information. It may help us understand how a cancer is likely to behave, whether a certain treatment is more likely to work, or whether a treatment is working at all.

In other words, a biomarker helps us move beyond just naming the cancer and start understanding its personality.That matters because not all cancers behave the same way, even when they start in the same organ. Two patients may both have lung cancer or breast cancer, but the biology underneath can be very different. Biomarkers help doctors see some of those differences more clearly.

In this blog, I’ll walk through what a biomarker is, how biomarkers are used in cancer care, common examples, and why they matter to patients.

What is a biomarker in cancer?

A biomarker is a biological signal that tells us something meaningful about a cancer. Sometimes that signal comes from the tumor itself. Sometimes it comes from the blood. Sometimes it comes from normal tissue or the immune system. The important point is not where it comes from, but what it helps us understand.

Biomarkers may help answer questions like:

• What type of cancer is this, really?
• How aggressive is it likely to be?
• Is this treatment likely to work?
• Is the cancer responding?
• Is there a higher risk of recurrence?
  

The cleanest way I can put it is this: A biomarker is a clue about cancer biology. It gives us information we usually cannot get from a scan alone, and often not even from the pathologist simply looking at the cancer under a microscope.

Why do biomarkers matter in cancer care?

Because cancer treatment has become more personalized. Years ago, treatment decisions were driven mainly by:

• where the cancer started
• how far it had spread
• what it looked like under the microscope
  

Those things still matter. A lot. But now we also know that cancers arising in the same organ can behave very differently depending on the molecular signals driving them. Biomarkers help us identify those signals. That can matter in several ways.

1. Biomarkers can help choose the right treatment. This is one of the biggest reasons biomarkers matter. Some treatments only work well if a certain biomarker is present. If the biomarker is absent, the treatment may be far less useful, or may not work at all.

For example, some lung cancers have an EGFR mutation, and that can make a patient eligible for a treatment specifically designed to target that pathway. Some breast cancers are HER2-positive, which opens the door to HER2-directed therapies.

This is a big shift in cancer care. Instead of treating every cancer from the same organ the exact same way, doctors can sometimes match treatment more closely to the biology of the tumor.

2. Biomarkers can help estimate prognosis. Some biomarkers help doctors understand whether a cancer is more likely to behave aggressively or less aggressively. That does not mean biomarkers predict the future with certainty. Cancer is not that simple. But they can help us estimate risk and decide how aggressive treatment needs to be.

3. Biomarkers can help avoid unnecessary treatment. This is an underrated but very important point. Sometimes a biomarker helps us identify patients who may not need more treatment. That can spare patients side effects, time, expense, and emotional burden. One of the clearest examples is Oncotype DX in certain breast cancers.

In the right setting, this test can help doctors estimate whether chemotherapy is likely to add enough benefit to be worth it. That matters. In oncology, good care is not just about intensifying treatment. Sometimes it is about safely backing off.

4. Biomarkers can help monitor response or recurrence. Some biomarkers can be followed over time in blood or tissue to help doctors understand whether treatment is working or whether a cancer may have returned. This overlaps with the idea of tumor markers, which are a specific type of biomarker. Not all biomarkers are tumor markers, but some tumor markers are biomarkers.

What are some common examples of biomarkers in cancer?

Here are a few of the most common or important examples patients may hear about.

• Hormone receptor status in breast cancer. In breast cancer, doctors often check whether the cancer cells have receptors for estrogen or progesterone. If they do, that is important because those cancers may respond to hormone-blocking treatment. This is a classic example of a biomarker directly shaping treatment decisions.
• HER2. This is another important biomarker in breast cancer, and sometimes in other cancers as well. If a tumor is HER2-positive, that tells us the cancer may respond to drugs specifically designed to target HER2.
• EGFR. In some lung cancers, doctors test for an EGFR mutation. This can open the door to targeted therapies that may work better than standard treatment in the right patient.
• PD-L1. This biomarker is sometimes used to help estimate whether immunotherapy may be helpful. This is an area where patients sometimes get confused, because PD-L1 can be useful without being absolute. A high result does not guarantee success, and a low result does not always mean immunotherapy has no role. It is one piece of the decision-making process.
• MSI-H / dMMR. These biomarkers relate to how well tumor cells repair DNA damage. Cancers that are MSI-high or dMMR may behave differently and may respond especially well to certain immunotherapies. This is one of the more important biomarker advances in modern oncology because it crosses traditional organ boundaries.
• BRCA1 and BRCA2. These genes are often discussed in breast, ovarian, prostate, and pancreatic cancers. Sometimes they are inherited. Sometimes they are found only in the tumor. Either way, they can matter because they may affect treatment options and, in some cases, family counseling.
• Oncotype DX and other genomic assays. These are not single biomarkers but rather groups of genes analyzed together to help estimate recurrence risk and the likely benefit of treatment. They are most helpful in specific settings and are not used for every patient.
  

What is the difference between a biomarker and a tumor marker?

Patients often hear these terms used almost interchangeably, but they are not exactly the same.

A biomarker is the broader category. It includes any measurable biological feature that gives useful information about cancer. A tumor marker is usually a more specific term, often referring to something measurable in the blood, like PSA, CEA, or CA-125.

So the easiest way to think about it is: All tumor markers are biomarkers, but not all biomarkers are tumor markers.

How are biomarkers tested?

Biomarkers can be tested in different ways depending on the question doctors are trying to answer.

Testing may be done using:

• tumor tissue from a biopsy or surgery
• blood samples
• bone marrow samples
• sometimes other body fluids
  

Common testing methods include:

• immunohistochemistry
• molecular testing
• next-generation sequencing
• fluorescence in situ hybridization
• blood-based assays, sometimes called liquid biopsy
  

The details can get technical quickly, but for patients, the important point is that the test is usually chosen based on the cancer type and the clinical question.

What are the strengths of biomarkers?

Biomarkers have changed cancer care in some very meaningful ways.

• They help personalize treatment. This is the biggest strength. Biomarkers can help match a treatment to the cancer biology rather than treating everyone the same.
• They can help predict benefits. Some biomarkers help identify patients more likely to benefit from a specific drug or treatment approach.
• They can help avoid overtreatment. This is one of the most humane uses of biomarkers. Sometimes they help us safely avoid treatment that is unlikely to help enough to justify the downside.
• They can improve clinical trial matching. Biomarkers are increasingly used to identify patients who may be candidates for specific clinical trials testing targeted therapies or immunotherapies.
  

What are the limitations of biomarkers?

This part matters just as much as the promise.

• Biomarkers are not perfect. A biomarker may be helpful without being absolute. It may increase or decrease the chance that a treatment works, but it rarely gives a yes-or-no answer with complete certainty.
• Tumors are not always uniform. One part of a tumor may look slightly different from another part. A biopsy captures a sample, not always the entire story. This is one reason biomarker interpretation can be complicated.
• Biomarkers can change over time. Cancer biology can evolve, especially after treatment. A biomarker result from the time of diagnosis may not fully reflect the biology of a recurrent or metastatic cancer later on.
• Not every patient needs every biomarker test. Biomarker testing is powerful, but more testing is not always better. The right test depends on the cancer type, stage, treatment setting, and what decision the result might actually change.
• Sometimes the result is interesting but not actionable. This happens more than patients realize. A report may identify a mutation or molecular feature that is scientifically interesting but does not yet change treatment in a practical way.
  

What should patients ask about biomarker testing?

If your doctor orders biomarker testing, a few questions can help bring the conversation down to earth:

• What are you hoping to learn from this test?
• Will the result change my treatment options?
• Is this being tested in the tumor, the blood, or both?
• Does this test help with prognosis, treatment choice, or both?
• If the result is negative, does that rule anything out?
• If the result is positive, what would it change?
  

Those questions usually get to the heart of whether the test is likely to matter in a practical way.

–

Biomarkers matter because they help doctors see cancer in higher resolution.

Instead of treating cancer based only on where it started, we can sometimes treat it based on what is driving it. That has made cancer care more precise, and in many cases more effective.

But biomarkers are not magic. They do not replace good judgment, pathology, imaging, or the broader clinical picture. They are one more layer of information, and like every tool in oncology, they work best when interpreted in context.

Cancer care can feel overwhelming because patients are asked to absorb so much unfamiliar language, often at one of the hardest moments of their lives. My hope is that understanding what a biomarker is can make these conversations feel a little less abstract and a little more manageable.

Disclaimer: This is for educational purposes only. This is not medical advice. Talk to your doctor before making any medical decisions.

–

To learn more, browse our library of cancer related topics.

Hire PRIMR to create custom video content for your clinical trial or medical product today.

‍

FAQs:

Is a biomarker the same as a genetic mutation?

Not always. Some biomarkers are genetic mutations, but others are proteins, receptors, patterns of gene expression, or features of how a tumor behaves. “Biomarker” is the broader term.

Does every cancer patient need biomarker testing?

No. Some cancers rely heavily on biomarker testing. In others, it may be less useful or only helpful in certain stages or situations.

Can a biomarker tell whether a treatment will definitely work?

Usually not. Biomarkers often help estimate the chance that a treatment will work, but they rarely offer certainty.

Can biomarker results change over time?

Yes. Sometimes cancer biology changes, especially after treatment or as cancer spreads. That is one reason doctors may repeat testing later in the course of care.

Are biomarkers only used for advanced cancer?

No. Biomarkers can matter in both early-stage and advanced cancer. In some early-stage settings, they help decide whether more treatment is needed. In advanced cancer, they often help guide targeted therapy or immunotherapy.